Wednesday, July 8, 2026

biotech · Respiratory Distress Syndrome · Cardiogenic Shock · WINT

WINDTREE THERAPEUTICS INC

Windtree Therapeutics is a biotech organization headquartered in Warrington, USA. It trades on NYSE under ticker WINT. Primary therapeutic focus areas include Respiratory Distress Syndrome, Cardiogenic Shock, Respiratory

2600 Kelly Rd., Suite 100, Warrington, PA 18976, US HQ
1992 Founded
17 Employees
Public company Type
WINT · NYSE Ticker
Company details
Status
Public
HQ
2600 Kelly Rd., Suite 100, Warrington, PA 18976, US
Founded
1992
Employees
17
Programs
15
Drugs
9
Patents
4
Clinical program

Placebo

Phase 2 · small molecule · Acute Decompensated Heart Failure

Placebo for Acute Decompensated Heart Failure is a Phase 2 program (small_molecule) at WINDTREE THERAPEUTICS INC /DE/ with 1 ClinicalTrials.gov record(s).

← All WINDTREE THERAPEUTICS INC /DE/ projects Phase 2 small molecule completed

Internal code CVT-CV-002

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
WINDTREE THERAPEUTICS INC /DE/
Phase
Phase 2
Modality
small_molecule
Indication
Acute Decompensated Heart Failure
Status
completed
Trials
1

Clinical trials